Clinical trial
ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer
NCT00496665 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00496665 |
|---|---|
| Title | ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer |
| Official title | A Phase I Study of ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | AstraZeneca Industry Massachusetts General Hospital Brigham and Women's Hospital |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | Vandetanib, Cyclophosphamide, Methotrexate |
| Enrollment | 25 |
| Start date | Jul 1, 2007 |
| Primary completion | Aug 1, 2008 |
| Completion | Mar 1, 2009 |
| First posted | Jul 4, 2007 |
| Last update posted | Nov 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: